IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy

Nature Medicine

Volumn 13, Issue 3, 2007, Pages 354-360

  Berner, Vanessa ^a   Liu, Haiyan ^a   Zhou, Qing ^a   Alderson, Kory L ^a   Sun, Kai ^a   Weiss, Jonathan M ^c   Back, Timothy C ^c   Longo, Dan L ^d   Blazar, Bruce R ^e   Wiltrout, Robert H ^c   Welniak, Lisbeth A ^a   Redelman, Doug ^b   Murphy, William J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD40 ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; FEMALE; IMMUNIZATION; KIDNEY CANCER; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MELANOMA; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; CLONAL DELETION; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; KIDNEY NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC;

MUS;

EID: 33847724350     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1554     Document Type: Article

References (25)

1. + cell responses. J. Immunol. 170, 2727-2733 (2003).
2. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R. & Melief, C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
3. Honeychurch, J., Glennie, M.J., Johnson, P.W. & Illidge, T.M. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 102, 1449-1457 (2003).
4. Zhou, Q., Kozel, T.R. & Murphy,, W.J. Immunotherapy protects from direct cerebral infection of Cryptococcus in mice by activation of microglial cells. J. Immunol. (in the press).
5. Hamilton, S.E., Wolkers, M.C., Schoenberger, S.P. & Jameson, S.C. The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat. Immunol. 7, 475-481 (2006).
6. + T lymphocytes. Nature 421, 852-856 (2003).
7. + T cell memory. Science 297, 2060-2063 (2002).
8. Shedlock, D.J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).
9. Sun, J.C. & Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
10. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93 (2005).
11. + T-lymphocyte subsets using quantitative real-time PCR. Scand. J. Immunol. 58, 601-606 (2003).
12. Elsasser-Beile, U., Rindsfuser, M., Grussenmeyer, T., Schultze-Seemann, W. & Wetterauer, U. Enhanced expression of IFN-gamma mRNA in CD4(+) or CD8(+) tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer. Br. J. Cancer 83, 637-641 (2000).
13. Curotto de Lafaille, M.A. & Lafaille, J.J. CD4(+) regulatory T cells in autoimmunity and allergy. Curr. Opin. Immunol. 14, 771-778 (2002).
14. Kennedy, M.K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
15. Schluns, K.S., Williams, K., Ma, A., Zheng, X.X. & Lefrancois, L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. 168, 4827-4831 (2002).
16. + T cells. J. Exp. Med. 195, 1515-1522 (2002).
17. Marks-Konczalik, J. et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97, 11445-11450 (2000).
18. Wigginton, J.M. et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108, 51-62 (2001).
19. Switaj, T. et al. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. 10, 4165-4175 (2004).
20. Sobek, V., Balkow, S., Korner, H. & Simon, M.M. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes. Eur. J. Immunol. 32, 2490-2499 (2002).
21. Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
22. + T cells after acute infection. Nat. Immunol. 5, 927-933 (2004).
23. Schmaltz, C. et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8, 1433-1437 (2002).
24. Yang, Y.G., Dey, B.R., Sergio, J.J., Pearson, D.A. & Sykes, M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J. Clin. Invest. 102, 2126-2135 (1998).
25. Hunter, K.W., Jr., DuPre, S. & Redelman, D. Microparticulate beta-glucan upregulates the expression of B7.1, B7.2, B7-H1, but not B7-DC on cultured murine peritoneal macrophages. Immunol. Lett. 93, 71-78 (2004).